Johnson & Johnson announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has granted a Type II variation to the labeling of its subcutaneous Darzalex (daratumumab), allowing patients or their caregivers to self‑administer the drug from the fifth dose onward after appropriate training and a healthcare professional’s determination.
This approval marks the first time an oncology injectable has been cleared for self‑administration in Europe, a milestone that could reduce the need for frequent hospital visits and give patients greater control over their treatment schedule. The change is expected to ease pressure on clinical resources while maintaining the safety and efficacy profile that has made Darzalex a cornerstone of multiple‑myeloma therapy.
J&J’s decision to pursue self‑administration reflects its broader strategy of leveraging Halozyme’s ENHANZE drug‑delivery technology to improve patient experience. By expanding Darzalex’s utility across its approved indications—multiple myeloma, smouldering multiple myeloma, and light‑chain amyloidosis—the company strengthens its competitive position and opens new avenues for market share growth in a crowded oncology landscape.
Thomas Lund, MD, PhD, head of the Hematological Section at Vejle Hospital, noted, "For many patients living with multiple myeloma, treatment can involve frequent hospital visits and the challenge of fitting care around everyday life. The possibility for self‑administration of daratumumab subcutaneous represents meaningful progress for those who would prefer the opportunity for greater flexibility in how or where they receive their care. For the medical community, it reduces pressure on healthcare systems and provides healthcare professionals with more choice in how they tailor treatment to individual needs and preferences, while maintaining the well‑established safety profile and efficacy of daratumumab."
In its most recent quarterly report, J&J reported adjusted earnings per share of $2.46 and revenue of $24.6 billion, both surpassing analyst expectations. The company reiterated its 2026 outlook, projecting sales of $100.5 billion, a figure that underscores confidence in the continued demand for its oncology portfolio.
Analysts have maintained a moderate buy rating on J&J, citing the company’s strong earnings performance and the strategic significance of the self‑administration approval. The guidance for 2026 reflects a belief that the expanded access to Darzalex will support sustained growth in the oncology segment.
The self‑administration approval positions J&J to capture a larger share of the multiple‑myeloma market and sets a precedent for future oncology injectables. By combining patient‑centric delivery with proven clinical efficacy, the company is poised to reinforce its leadership in the field and drive long‑term value for stakeholders.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.